Immix Biopharma, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company with common stock registered under ticker IMMX and a development program centered on NXC-201 for relapsed/refractory AL Amyloidosis. Current reports include Regulation FD and other-event disclosures for NEXICART-2 clinical updates and regulatory-development matters.
The company’s SEC record also covers capital-structure activity, including at-the-market sales agreements, shelf registration statements, registered offerings, private placements, warrants and resale registration rights. Proxy materials disclose director elections, auditor ratification, annual-meeting voting results and other governance matters.
Immix Biopharma, Inc. (IMMX) agreed to issue and sell 11,363,637 shares of common stock at a public offering price of $11.00 per share in an underwritten offering. The company expects $125 million in gross proceeds and estimates approximately $117.1 million in net proceeds after underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on September 30, 2026, subject to satisfaction of customary conditions.
Immix intends to use net proceeds for NXC-201 development, working capital and general corporate purposes. J.P. Morgan Securities LLC is the sole book-running manager. The offering uses the company’s shelf registration statement, declared effective on January 22, 2026, and a prospectus supplement dated September 29, 2026. It included participation from new and existing institutional investors, including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments L.P. and Wellington Management.
Immix Biopharma, Inc. is offering 11,363,637 shares of common stock at $11.00 per share, for a stated aggregate public offering price of $125,000,007. Estimated net proceeds are approximately $117.1 million after underwriting discounts and estimated offering expenses; the company intends to use them for NXC-201 clinical development, working capital and general corporate purposes. The prospectus estimates immediate dilution of $6.83 per share for offering purchasers, with pro forma, as-adjusted net tangible book value of approximately $4.17 per share.
Updated Phase 2 NEXICART-2 data report complete responses in 40 of 45 relapsed/refractory AL amyloidosis patients (89%), as assessed by an independent review committee. All 25 new patients were either in complete response or already MRD-negative. Four pending patients who were already MRD-negative could potentially increase the future complete response rate to up to 98% (44/45). No relapses had been observed to date among patients who reached complete response or MRD-negativity.
Immix Biopharma, Inc. (IMMX) reported an interim Phase 2 NEXICART-2 update: NXC-201 produced an 89% (40/45) complete response rate across all 45 enrolled patients, as assessed by an independent review committee. All 25 new patients were either in complete response or MRD-negative: 21 were in complete response and four were MRD-negative. Immix said bone-marrow MRD-negativity in four pending patients could bring the complete response rate to up to 98% (44/45). All patients who achieved MRD-negativity reached complete response within one year of treatment.
No relapses have been observed to date among patients who reached complete response or MRD-negativity, and no neurotoxicity or enterocolitis has been observed to date. Safety data through August 4, 2026, were generally consistent with previous NEXICART-2 safety data. The final readout and BLA submission are planned for mid-2027.
Immix Biopharma, Inc. is reported to have a significant shareholder group led by Eventide Asset Management, LLC. As of June 30, 2026, Eventide, as investment adviser to the Eventide Healthcare & Life Sciences Fund, is the beneficial owner of 3,891,019 shares of Immix Biopharma common stock, representing 5.6% of the outstanding common stock. Eventide holds sole voting and dispositive power over these shares, while individuals Finny Kuruvilla, M.D., Ph.D. and Robin C. John each report shared voting and dispositive power over the same 3,891,019 shares. The three parties have agreed to act as joint reporting persons regarding this ownership.
Janus Henderson Group Ltd. reports beneficial ownership of common stock of Immix Biopharma, Inc. through its investment adviser subsidiaries. The asset managers collectively may be deemed the beneficial owner of 9,783,192 shares of common stock, representing 14.0% of the class. All voting and investment discretion is exercised on behalf of client accounts referred to as Managed Portfolios, which have the economic right to dividends and sale proceeds. Janus Henderson and its asset managers disclaim ownership of such economic rights. Voting and dispositive power over all reported shares is shared, with no sole voting or dispositive power reported.
Immix Biopharma, a clinical-stage cell therapy company focused on CAR-T candidate NXC-201, reported a net loss of $11.6 million for the quarter ended June 30, 2026, compared with $6.6 million a year earlier. Operating expenses were $12.5 million, including general and administrative expenses of $7.1 million and research and development costs of $5.3 million. Interest income rose to $0.9 million, reflecting larger cash and investment balances.
For the first half of 2026, net loss was $21.6 million versus $11.2 million in the prior-year period, on total operating expenses of $23.3 million. Loss per share was $0.36, compared with $0.37, as the weighted-average share count increased to 59.6 million from 29.8 million.
As of June 30, 2026, cash, cash equivalents and short-term investments totaled approximately $232.1 million, plus $2.1 million of long-term U.S. Treasury investments. This position reflects a May 2026 underwritten offering that generated approximately $140.7 million in net proceeds and sales under a $100 million at-the-market program. Total liabilities were $10.2 million and stockholders’ equity was $228.9 million. The company believes its existing cash, cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements for at least the next 12 months as it advances the Phase 1b/2 NEXICART-2 trial and other development activities, supported in part by an $8.0 million CIRM grant.
Immix Biopharma, Inc. reported that as of July 17, 2026, Richard Graydon has been terminated and is no longer with the company. The company states that the departure is for reasons unrelated to his activities at Immix Biopharma.
Given his short tenure, management believes this change has no material effect on the business.
Janus Henderson Group plc files Amendment No. 2 to a Schedule 13G/A reporting ownership of 9,090,732 shares of Immix Biopharma, Inc. The filing states the Asset Managers controlled by Janus Henderson exercise shared voting and dispositive power over those shares, representing 13.0% of the class as disclosed. The filing notes that most Managed Portfolios hold the shares for clients and that only the Janus Henderson Biotech Innovation Master Fund Ltd. holds more than 5% of the class.
The filing is signed by a compliance officer on 06/05/2026 and references exhibits including a Power of Attorney and Item 7 details.
Immix Biopharma, Inc. reported the final voting results from its 2026 Annual Meeting of stockholders held on May 22, 2026. Stockholders elected all listed director nominees, including Ilya Rachman, Gabriel Morris and others, with each receiving over 34 million votes in favor and relatively few votes withheld.
Each director election also recorded 6,445,683 or 6,445,684 broker non-votes. A second proposal was approved with 42,276,496 votes for, 11,526 against and 18,442 abstentions, indicating strong support from voting shareholders for the matters presented.
Immix Biopharma director Helen C. Adams received new equity awards as part of her compensation. She was granted 6,250 restricted stock units of common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual shareholder meeting, subject to her continued service.
Adams was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036. These options vest in substantially equal monthly installments over 12 months following the grant date, or sooner if the 2027 annual meeting occurs earlier. After the RSU grant, her direct common stock holdings total 181,004 shares.